164 related articles for article (PubMed ID: 15975706)
1. Mechanisms of bone invasion and metastasis in human neuroblastoma.
Sohara Y; Shimada H; DeClerck YA
Cancer Lett; 2005 Oct; 228(1-2):203-9. PubMed ID: 15975706
[TBL] [Abstract][Full Text] [Related]
2. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of invasion and metastasis in human neuroblastoma.
Ara T; DeClerck YA
Cancer Metastasis Rev; 2006 Dec; 25(4):645-57. PubMed ID: 17160711
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
7. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
8. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
9. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
10. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast precursors, RANKL/RANK, and immunology.
Xing L; Schwarz EM; Boyce BF
Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
[TBL] [Abstract][Full Text] [Related]
13. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
14. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
15. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
[TBL] [Abstract][Full Text] [Related]
16. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
17. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
Yamamoto Y; Noguchi T; Udagawa N
Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
19. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Regulatory mechanisms of osteoclast differentiation and function].
Takahashi N
Clin Calcium; 2006 Jun; 16(6):940-47. PubMed ID: 16751689
[TBL] [Abstract][Full Text] [Related]
20. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
